Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

LATE-BREAKING ABSTRACTS

LATE-BREAKING ABSTRACTS Company, Genentech. G. Consultant; Eli Lilly and Company, Genentech. LATE-BREAKING PLENARY D.R. Spigel: None. R.C. Hermann: B. Independent Contractor; Eli Lilly and Company. J. Liu: A. Employee; Eli Lilly and Company. K. Stock; Eli Lilly and Company. S.C. Guba: A. Employee; Eli Lilly and Company. K. LBPL1 Stock; Eli Lilly and Company. P. Bonomi: E. Research Grant; Eli Lilly A Randomized, Open-label, Phase 3, Superiority Study and Company, ImClone, Genentech. R. Govindan: F. Honoraria; Covidien, Of Pemetrexed (Pem)+Carboplatin (Cb)+Bevacizumab Pfizer, Astra-Zeneca, GSK, Boehringer-Ingelheim, BMS, Genentech. G. (B) Followed By Maintenance Pem+B Versus Paclitaxel Consultant; Covidien, BMS, Pfizer, GSK, Boehringer-Ingelheim, Astra- (Pac)+Cb+B Followed By Maintenance B In Patients (pts) Zeneca, Genentech. With Stage IIIB Or IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC) 1 2 3 4 5 J. Patel , M. A. Socinski , E. B. Garon , C. H. Reynolds , D. R. Spigel , R. LBPL2 6 7 7 8 9 1 C. Hermann , J. Liu , S. C. Guba , P. Bonomi , R. Govindan , Northwestern Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial University, Chicago, IL, University of Pittsburgh Medical Center Cancer of Bavituximab Plus Docetaxel in Patients with Previously Pavilion, Pittsburgh, PA, University of California http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

LATE-BREAKING ABSTRACTS

Journal of Thoracic Oncology , Volume 7 – Sep 1, 2012
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/late-breaking-abstracts-0Sn1vSdKIL

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

Company, Genentech. G. Consultant; Eli Lilly and Company, Genentech. LATE-BREAKING PLENARY D.R. Spigel: None. R.C. Hermann: B. Independent Contractor; Eli Lilly and Company. J. Liu: A. Employee; Eli Lilly and Company. K. Stock; Eli Lilly and Company. S.C. Guba: A. Employee; Eli Lilly and Company. K. LBPL1 Stock; Eli Lilly and Company. P. Bonomi: E. Research Grant; Eli Lilly A Randomized, Open-label, Phase 3, Superiority Study and Company, ImClone, Genentech. R. Govindan: F. Honoraria; Covidien, Of Pemetrexed (Pem)+Carboplatin (Cb)+Bevacizumab Pfizer, Astra-Zeneca, GSK, Boehringer-Ingelheim, BMS, Genentech. G. (B) Followed By Maintenance Pem+B Versus Paclitaxel Consultant; Covidien, BMS, Pfizer, GSK, Boehringer-Ingelheim, Astra- (Pac)+Cb+B Followed By Maintenance B In Patients (pts) Zeneca, Genentech. With Stage IIIB Or IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC) 1 2 3 4 5 J. Patel , M. A. Socinski , E. B. Garon , C. H. Reynolds , D. R. Spigel , R. LBPL2 6 7 7 8 9 1 C. Hermann , J. Liu , S. C. Guba , P. Bonomi , R. Govindan , Northwestern Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial University, Chicago, IL, University of Pittsburgh Medical Center Cancer of Bavituximab Plus Docetaxel in Patients with Previously Pavilion, Pittsburgh, PA, University of California

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Sep 1, 2012

There are no references for this article.